CommentSorafenib and novel multikinase inhibitors in AML
References (10)
- et al.
Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation
Blood
(2009) - et al.
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
Blood
(2013) - et al.
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis
Blood
(2002) - et al.
Toward individualized therapy in acute myeloid leukemia: a contemporary review
JAMA Oncol
(2015) - et al.
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
Lancet Oncol
(2015)
There are more references available in the full text version of this article.
Cited by (6)
Sorafenib regulates c-CBL gene-mediated chemoresistance in acute myeloid leukemia cells
2023, Hematology (United Kingdom)Bypassing drug resistance by triggering necroptosis: Recent advances in mechanisms and its therapeutic exploitation in leukemia
2018, Journal of Experimental and Clinical Cancer ResearchRepurposing anticancer drugs for targeting necroptosis
2018, Cell CyclePrecision therapy for acute myeloid leukemia
2018, Journal of Hematology and OncologyLiposomal cytarabine and daunorubicin (CPX-351) for treatment of acute myeloid leukemia
2017, Expert Opinion on Orphan Drugs
Copyright © 2015 Elsevier Ltd. All rights reserved.